Phase II study of Bevacizumab plus modified OPTIMOX1 in patients with unresectable advanced/recurrent colorectal cancer
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: 1-6 Course Bevacizumab+mFOLFOX6 7-18 Course Bevacizumab+sLV5FU2 19- Course Bevacizumab+mFOLFOX6 Primary outcome(s): Duration of disease control Study Design: Single arm Non-randomized
创建时间：
2008-06-15
